FI106259B - Menetelmä terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI106259B
FI106259B FI942310A FI942310A FI106259B FI 106259 B FI106259 B FI 106259B FI 942310 A FI942310 A FI 942310A FI 942310 A FI942310 A FI 942310A FI 106259 B FI106259 B FI 106259B
Authority
FI
Finland
Prior art keywords
phenyl
methyl
compound
tetrahydro
cyclohexen
Prior art date
Application number
FI942310A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI942310A0 (fi
FI942310A (fi
Inventor
Lawrence David Wise
Bradley William Caprathe
Juan Carlos Jaen
Dennis Michael Downing
Stephen Joseph Johnson
Iii William John Smith
Jonathan Wright
David Juergen Wustrow
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of FI942310A0 publication Critical patent/FI942310A0/fi
Publication of FI942310A publication Critical patent/FI942310A/fi
Priority to FI980471A priority Critical patent/FI107383B/fi
Application granted granted Critical
Publication of FI106259B publication Critical patent/FI106259B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI942310A 1991-11-20 1994-05-18 Menetelmä terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi FI106259B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI980471A FI107383B (fi) 1991-11-20 1998-03-02 Menetelmä terapeuttisesti käyttökelpoisten piperatsiinijohdannaisten valmistamiseksi

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US79520791A 1991-11-20 1991-11-20
US79520791 1991-11-20
US07/957,277 US5314896A (en) 1991-11-20 1992-10-15 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
US95727792 1992-10-15
PCT/US1992/009583 WO1993010092A1 (en) 1991-11-20 1992-11-05 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
US9209583 1992-11-05

Publications (3)

Publication Number Publication Date
FI942310A0 FI942310A0 (fi) 1994-05-18
FI942310A FI942310A (fi) 1994-07-15
FI106259B true FI106259B (fi) 2000-12-29

Family

ID=27121601

Family Applications (2)

Application Number Title Priority Date Filing Date
FI942310A FI106259B (fi) 1991-11-20 1994-05-18 Menetelmä terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi
FI980471A FI107383B (fi) 1991-11-20 1998-03-02 Menetelmä terapeuttisesti käyttökelpoisten piperatsiinijohdannaisten valmistamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI980471A FI107383B (fi) 1991-11-20 1998-03-02 Menetelmä terapeuttisesti käyttökelpoisten piperatsiinijohdannaisten valmistamiseksi

Country Status (20)

Country Link
US (2) US5314896A (no)
EP (2) EP0545095A1 (no)
JP (1) JP3193718B2 (no)
KR (1) KR100234600B1 (no)
AT (1) ATE206398T1 (no)
AU (1) AU664872B2 (no)
CA (1) CA2122911C (no)
CZ (1) CZ284181B6 (no)
DE (1) DE69232099T2 (no)
DK (1) DK0613465T3 (no)
ES (1) ES2165360T3 (no)
FI (2) FI106259B (no)
HU (1) HU218935B (no)
NO (1) NO180632C (no)
NZ (1) NZ245174A (no)
PT (1) PT613465E (no)
RU (1) RU2116297C1 (no)
SG (1) SG46641A1 (no)
SK (1) SK280812B6 (no)
WO (1) WO1993010092A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401692A (en) * 1993-06-15 1995-03-28 Texas Instruments Incorporated Method for minimizing particle generation on a wafer surface during high pressure oxidation of silicon
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US5468767A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antidepressant 3-(aminocycloalkenyl)-indole-5-nitrile derivatives
US5710277A (en) * 1994-09-12 1998-01-20 Warner-Lambert Company Process for R (+) 1,2,3,6-tetrahydro-4-phenyl-1- (3-phenyl-3-cyclohexen-1-yl)methyl!pyridine, a central nervous system agent
US5773616A (en) * 1995-02-15 1998-06-30 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
CA2213197C (en) * 1995-02-15 2001-08-07 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
CN1184478A (zh) * 1995-03-22 1998-06-10 大正制药株式会社 噻唑衍生物
US6245768B1 (en) 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5602168A (en) * 1995-07-10 1997-02-11 Neurogen Corporation 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
US5656632A (en) * 1995-06-05 1997-08-12 Neurogen Corporation 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
US5633724A (en) * 1995-08-29 1997-05-27 Hewlett-Packard Company Evanescent scanning of biochemical array
GB9523462D0 (en) * 1995-11-16 1996-01-17 Merck Sharp & Dohme Therapeutic agents
EP1068184B1 (en) * 1998-04-08 2002-09-04 Wyeth N-aryloxyethylamine derivatives for the treatment of depression
WO2000040579A1 (en) * 1999-01-07 2000-07-13 American Home Products Corporation New 1,4-disubstituted cyclohexane derivatives for the treatment of depression
US6200994B1 (en) 1999-01-07 2001-03-13 American Home Products Corp 1,4-Disubstituted cyclohexane derivatives for the treatment of depression
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6245780B1 (en) * 1999-04-22 2001-06-12 American Home Products Corp Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression
CA2379021C (en) 1999-08-23 2009-10-27 Solvay Pharmaceuticals B.V. New phenylpiperazines
US6780305B2 (en) * 2001-02-20 2004-08-24 Fuji Photo Film Co., Ltd. Method for producing support for planographic printing plate, support for planographic printing plate, and planographic printing plate precursor
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
US20040197284A1 (en) 2003-04-04 2004-10-07 Frederic Auguste Cosmetic composition comprising a volatile fatty phase
UY28538A1 (es) 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
EP2102145A4 (en) 2006-12-21 2014-06-18 Abbott Lab PROCESS FOR THE PREPARATION AND ISOLATION OF INDIVIDUAL STEREOISOMERS OF 1-AMINO, 3-SUBSTITUTED PHENYLCYCLOPENTAN CARBOXYLATES
UY30829A1 (es) * 2006-12-21 2008-07-31 Abbott Lab Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597921A (en) * 1984-07-26 1986-07-01 Northern Telecom Limited Provision of plastic insulation upon an electrical conductor
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US4975445A (en) * 1989-12-06 1990-12-04 Warner-Lambert Company Substituted cyclohexenes as central nervous system agents
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
US5124332A (en) * 1991-01-28 1992-06-23 Warner-Lambert Company Substituted indoles as central nervous system agents

Also Published As

Publication number Publication date
EP0545095A1 (en) 1993-06-09
JPH07501075A (ja) 1995-02-02
AU3129193A (en) 1993-06-15
NO941884D0 (no) 1994-05-19
HU218935B (hu) 2001-01-29
CA2122911A1 (en) 1993-05-27
PT613465E (pt) 2002-03-28
DE69232099T2 (de) 2002-06-06
NO180632B (no) 1997-02-10
ATE206398T1 (de) 2001-10-15
HU9401468D0 (en) 1994-08-29
EP0613465B1 (en) 2001-10-04
SK280812B6 (sk) 2000-08-14
ES2165360T3 (es) 2002-03-16
CA2122911C (en) 2003-10-14
NO941884L (no) 1994-05-19
CZ116194A3 (en) 1994-11-16
EP0613465A1 (en) 1994-09-07
NZ245174A (en) 1995-09-26
RU2116297C1 (ru) 1998-07-27
SK56994A3 (en) 1995-02-08
FI980471A0 (fi) 1998-03-02
FI942310A0 (fi) 1994-05-18
CZ284181B6 (cs) 1998-09-16
WO1993010092A1 (en) 1993-05-27
KR100234600B1 (ko) 1999-12-15
FI942310A (fi) 1994-07-15
FI107383B (fi) 2001-07-31
DE69232099D1 (de) 2001-11-08
FI980471A (fi) 1998-03-02
NO180632C (no) 1997-05-21
SG46641A1 (en) 1998-02-20
US5314896A (en) 1994-05-24
HUT70520A (en) 1995-10-30
US5409931A (en) 1995-04-25
JP3193718B2 (ja) 2001-07-30
AU664872B2 (en) 1995-12-07
RU94028888A (ru) 1997-02-20
DK0613465T3 (da) 2002-02-04

Similar Documents

Publication Publication Date Title
FI106259B (fi) Menetelmä terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi
AU2015335694B2 (en) Indole carboxamide compounds useful as kinase inhibitors
JP2868313B2 (ja) Ｎ−置換複素環誘導体およびその製法
AU782763B2 (en) Cyclic amidine compounds
AU771920B2 (en) Heterocyclic compounds having effect of activating nicotinic acetylcholine alpha4beta2 receptor
CA2596393A1 (en) 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase for the treatment of anxiety, pain and other conditions
CA2188427C (en) Neurotransmitter release enhancers
US6900202B2 (en) Di-substituted imineheterocyclic compounds
EP3558965A1 (en) New quinoline and isoquinoline derivatives for treating pain and pain related conditions
NO338104B1 (no) Tetrahydroisoquinolin-sulfonamid-derivater, farmasøytiske preparater inneholdende slike og anvendelse derav som terapeutisk middel
CA2781858C (en) Modulators of tnf-.alpha. signaling
NO313196B1 (no) Pyrimidinylpyrazol-derivat, og antitumormiddel inneholdende dette
US6630469B2 (en) 5-HT7 receptor antagonists
DK156722B (da) Analogifremgangsmaade til fremstilling af 2-piperazinopyrimidinderivater
KR100425953B1 (ko) 티오피란유도체
BG108531A (bg) Нови х...'...роарилни производни, 'яхно'о пол"-аван... и използван...
AU600378B2 (en) Piperidine derivatives, their preparation and their application in therapy
IE66117B1 (en) Substituted cyclohexenes as central nervous system agents
CA2141810A1 (en) Amide derivatives
CZ46896A3 (en) Anti-migraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridinyl and -pyrimidinyl piperazines
AU782771B2 (en) Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholine receptors activators
SK17122002A3 (sk) Derivát heterocyklického aminoalkylpyridínu ako psychofarmaceutické činidlo, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
US5089497A (en) Substituted piperazines as central nervous system agents
Paluchowska et al. Modification of the structure of 4, 6‐disubstituted 2‐(4‐alkyl‐1‐piperazinyl) pyridines: synthesis and their 5‐HT2A receptor activity
BG108538A (bg) Нови индолови производни

Legal Events

Date Code Title Description
MA Patent expired